Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014783 | 0.77 | HRH3 (0.51) | HRH3KDM1AMAOBMAOACYP2D6 | |
| SCHEMBL23537862 | 0.77 | HRH3 (0.51) | HRH3KDM1AMAOBMAOACYP2D6 | |
| SCHEMBL6234715 | 0.74 | TP53 (0.43) | HRH3CREBBPKDM1AMAOBMAOA | |
| SCHEMBL29850459 | 0.70 | MAOB (0.50) | HRH3KDM1AMAOBMAOAALOX5 | |
| SCHEMBL17771702 | 0.70 | HRH3 (0.52) | HRH3CREBBPKDM1AMAOBMAOA | |
| SCHEMBL23774201 | 0.69 | HTR2A (0.54) | HRH3CREBBPKDM1AMAOBMAOA | |
| SCHEMBL281853 | 0.69 | MAOB (0.57) | HRH3KDM1AMAOBMAOAHTR2B | |
| SCHEMBL19764435 | 0.68 | KDM1A (0.77) | HRH3KDM1AMAOBMAOACYP2D6 | |
| SCHEMBL5442260 | 0.68 | HTR2C (0.65) | HRH3MAOBMAOAHTR2BHRH1 | |
| SCHEMBL5442264 | 0.68 | HTR2C (0.65) | HRH3MAOBMAOAHTR2BHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| EP-1507763-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097607-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | PPARD, PPARG, PPARA | HRH3 800/4885CREBBP 396/4885KDM1A 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.